Table 2.

Subgroup analysis of pretransplant and posttransplant characteristicsa

CharacteristicSandimmune + AZANeoral + MMF
Protocol Bx (n = 36)Control (n = 36)Protocol Bx (n = 17)Control (n = 12)
aBx, biopsy. Other abbreviations as in Table 1.
bValues represent median (minimum, maximum).
cANOVA P < 0.05 Sandimmune + AZA + Protocol Bx versus Neoral + MMF + Protocol Bx.
dANOVA P < 0.05 Sandimmune + AZA Control versus Neoral + MMF Control.
eValues are expressed as percentage of individuals experiencing 0, 1, or ≥2 rejection episodes.
fValues are expressed as percentage of individuals experiencing 0 or ≥1 rejection episode.
HLA matchingb2 (0,4)2 (0,5)2 (1,4)2 (1,4)
PRA (%)1.0 ± 0.90.5 ± 0.37.6 ± 5.0c6.6 ± 4.2d
Donor age (yr)30 ± 336 ± 339 ± 3c42 ± 4
Cold ischemia (min)963 ± 761015 ± 77904 ± 88928 ± 156
Delayed graft function19% (7 of 36)25% (9 of 36)29% (5 of 17)25% (3 of 12)
CsA level (μg/L)
mean 1 to 2 mo318 ± 11309 ± 7380 ± 5c366 ± 21d
mean 1 to 3 mo308 ± 8305 ± 6365 ± 8c351 ± 11d
Corticosteroid dose (g)
1 mo2.9 ± 0.32.6 ± 0.32.2 ± 0.32.4 ± 0.5
2 to 3 mo3.6 ± 0.32.8 ± 0.32.6 ± 0.32.0 ± 0.3
4 to 6 mo2.4 ± 0.32.4 ± 0.42.9 ± 0.6
Clinical rejection(0, 1, ≥2)e(0, 1, ≥2)(0, 1, ≥2)(0, 1, ≥2)
0 to 2 mo22, 39, 3911, 45, 4424, 76, 025, 42, 31
0 to 3 mo20, 33, 47 (0, ≥1)f8, 36, 56 (0, ≥1)23, 59, 18 (0, ≥1)25, 33, 42 (0, ≥1)
4 to 6 mo69, 3164, 3671, 2958, 42
7 to 12 mo89, 1167, 33100, 075, 25
Subclinical rejection
1 mo43%38%
2 mo32%25%
3 mo27%31%
6 mo15% (0, 1, ≥2)e25% (0, 1, ≥2)
0 to 3 mo31, 44, 2541, 35, 24
Creatinine (μmol/L)
6 mo135 ± 10137 ± 7136 ± 14151 ± 12
12 mo136 ± 12151 ± 13126 ± 7149 ± 14